China Oncology Congress 2019: China Resources Pharma Partners with MingShi Genomics to Advance Molecular Diagnostics

VCBeat (WeChat ID: vcbeat) learned that on September 19, 2019, the 22nd National Clinical Oncology Conference and the 2019 CSCO Annual Academic Conference grandly opened at the Xiamen International Conference Center. Upholding the conference theme of “Innovative Precision Research, Exploring Smart Healthcare,” and to further promote academic discussions among experts and scholars in the field of clinical oncology both domestically and internationally, CR PHARMA COMM and Mingshi Gene jointly hosted the CSCO Satellite Symposium titled “Application of Digital PCR in Precision Oncology Treatment” on the noon of the 20th, and simultaneously signed a strategic and business cooperation agreement.

The conference commenced with an opening address by Professor Ma Fei, Deputy Director of the Department of Medical Oncology at the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, and Chief Physician, representing clinical experts.

Subsequently, the General Manager of CR PHARMA COMM (Shanghai) Fengshan and Mr. Jiang Ying, General Manager of Mingshi Gene, signed the strategic cooperation agreement on behalf of their respective parties. Mr. Michael Levitt, Scientific Advisor to Mingshi Gene, 2013 Nobel Laureate in Chemistry, and Cahill Professor of Cancer Research at Stanford University, specially delivered a video message to congratulate the successful collaboration between CR PHARMA COMM and Mingshi Gene.

Group Photo at the Signing Ceremony

Guided by the principles of complementary advantages, mutual benefit, and common development, member enterprises of China Resources Pharmaceutical Commercial Group will fully leverage their channel resources and share the advantageous R&D capabilities of Mingshi Gene. With the Yangtze River Delta as a base, they plan to deepen cooperation in projects such as the Institute for Precision Medicine and the Permanent Gene Diagnosis Experience Center at the China International Import Expo, as well as implement strategies where capital empowers the real economy. These initiatives will be gradually expanded across China, further solidifying CR PHARMA COMM’s strategic layout in molecular biology testing, promoting the overall development of the biopharmaceutical industry, and demonstrating CR’s commitment to supporting the growth of outstanding domestic innovative enterprises.

During the subsequent satellite symposium, Professor Wu Shikai, Director of the Department of Medical Oncology at Peking University First Hospital; Professor Liu Xiaolong, Assistant to the President of Mengchao Hepatobiliary Hospital and Director of the Institute of Liver Diseases; Ms. Wei Yanjie, Product Manager in the Marketing Department of Bio-Rad Laboratories (Shanghai) Co., Ltd.; and Dr. Huang Xin, Chief Scientist at Mingshi Gene and Associate Professor at the University of Pittsburgh School of Medicine, delivered four thematic presentations centered on the conference theme. Their topics included “Current Status and Prospects of Precision Therapy for Breast Cancer,” “Application of Digital PCR in Precision Oncology,” “Application of ddPCR in Medical Research,” and “Liquid Biopsy in Oncology: Theory and Applications.” These insightful presentations attracted over 100 attendees, including clinical experts from various hospitals and investment professionals.

CR PHARMA COMM is a wholly-owned subsidiary of China Resources Group, dedicated to the integrated development of the domestic pharmaceutical industry. As a large-scale pharmaceutical manufacturer and distributor, its commercial arm, China Resources Pharmaceutical Commercial Group Co., Ltd., ranks among the top three pharmaceutical distributors in China. It boasts a nationwide distribution network covering 27 provinces, municipalities, and autonomous regions, supported by 170 logistics centers, along with global procurement channels. The company provides premium services, including leading pharmaceutical marketing, logistics and distribution, and comprehensive pharmaceutical supply chain solutions.

Mingshi Gene Technology (Shanghai) Co., Ltd. is a high-tech startup founded by Chinese scholars returning from studies in the United States. The company focuses on the development of novel targets for tumor therapy, innovative tumor cell therapies, and the clinical application of precision oncology treatments. With a mission to enhance human quality of life through genetic technologies, it adheres to a market-driven, R&D-centered business philosophy, striving to become a global leader in precision medicine and a competitively strong, China-based biotechnology enterprise with global reach.

Mingshi Genomics possesses extensive R&D experience in the field of digital PCR and features unique design solutions. The company has launched a series of molecular diagnostics for lung cancer and other tumors, particularly digital PCR reagents for liquid biopsy.